Combioxin.com

Combioxin.com has server used 128.65.195.32 (Switzerland) ping response time Hosted in RIPE Network Coordination Centre Register Domain Names at Infomaniak Network SA. This domain has been created 6 years, 25 days ago, remaining 8 years, 339 days. You can check the 9 Websites and blacklist ip address on this server

Domain information

Registrar WHOIS Server: whois.infomaniak.com

Registrar URL: http://www.infomaniak.com     See All 5,190+

Creation Date: 2015-09-22 6 years, 25 days

Updated Date: 2021-08-25 53 days ago

Expiry Date: 2030-09-22 8 years, 339 days left     See All

  Sign up for notifications near expiration

Registrar: Infomaniak Network SA

Abuse Email: [email protected]

Abuse Phone: 0041228203541

  Full details

Top 10 Hosting Providers

Registrar URLDomain CountsRegistrar NameAbuse Email
www.godaddy.com2,280,668GoDaddy.com, LLC[email protected]
www.tucows.com535,579Tucows Domains Inc.
networksolutions.com526,027Network Solutions, LLC[email protected]
www.namecheap.com333,839NameCheap, Inc.[email protected]
www.enom.com299,925eNom, LLC
www.publicdomainregistry.com294,948PDR Ltd. d/b/a PublicDomainRegistry.com[email protected]
www.whois.godaddy.com174,077GoDaddy.com, LLC[email protected]
www.fastdomain.com161,753FastDomain Inc.[email protected]
www.ionos.com159,2071&1 IONOS SE[email protected]
www.networksolutions.com149,653Network Solutions, LLC[email protected]

Full view & Download

Keywords Suggestions

Combioxin sa

Combioxin cal02

( Please select at least 2 keywords )

See More:   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z  

Hosting Provider

NetName: RIPE-ERX-128-65-0-0

Organization: RIPE Network Coordination Centre     See All 128,362+

Provider URL: Ripe.net

Hostname: h2web27.infomaniak.ch

IP Server: 128.65.195.32 Reg: 2010-11-03, Updated: 2010-11-17

Blacklist: Check Backlist Status

Country: Switzerland

Address: P.O. Box 10096, Amsterdam, 1001EB, NL

Latitude: 47.144901

Longitude: 8.155100

Name Server:

  • NS1.INFOMANIAK.CH
  • NS2.INFOMANIAK.CH

Abuse Email: [email protected]

Abuse Phone: +31205354444

Top 10 Hosting Providers

Website URLDomain CountsOrganizationAbuse Email
Google.com681,421Google LLC[email protected]
Godaddy.com650,706GoDaddy.com, LLC[email protected]
Cloudflare.com637,900Cloudflare, Inc.[email protected]
Endurance.com488,827The Endurance International Group, Inc.[email protected]
Amazon.com439,891Amazon Technologies Inc.[email protected]
297,405Domain Name Services
Amazonaws.com287,121Amazon Technologies Inc.[email protected]
Liquidweb.com159,971Liquid Web, L.L.C[email protected]
Squarespace.com150,667Squarespace, Inc.[email protected]
Ripe.net128,362RIPE Network Coordination Centre[email protected]

Full view & Download

List of found email addresses

  1: [email protected]

  2: [email protected]

  3: [email protected]

Find Websites hosted

1: Combioxin.com

2: Fragbox.com

3: Physiodermie.com

4: Lascco.com

5: Technobezz.com Changed to: 104.26.9.27

6: Home.bt.com Changed to: 68.142.68.29

7: Whatismyip.com Changed to: 104.27.195.88

8: Philia-sa.com

9: Franzosini.ch

At least 9 Sites on this server

Port Scanner (IP: 128.65.195.32)

Combioxin Restoring Health In Critically Ill Patients

  • Combioxin is a Swiss-based biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections
  • The company is currently running two parallel programs on an innovative technology designed to fight severe bacterial and viral infections.

Combioxin.com   DA: 17 PA: 17 MOZ Rank: 34

PR_CX_200504 Combioxin

  • About Combioxin: Combioxin SA is a Swiss-based clinical-stage biotechnology company founded in 2015
  • The company is committed to the development of disruptive treatments for severe infections
  • Contact details: Combioxin SA 8 rue de la Rôtisserie 1204 Geneva, Switzerland
  • [email protected] [email protected]

Combioxin.com   DA: 17 PA: 14 MOZ Rank: 32

Combioxin Biopôle

  • Combioxin is a Swiss-based biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections
  • The company is currently running two parallel programs on an innovative technology designed to fight severe bacterial and viral infections.

Biopole.ch   DA: 14 PA: 19 MOZ Rank: 35

Safety, Tolerability, Efficacy And

Combioxin SA: ClinicalTrials.gov Identifier: NCT02583373 Other Study ID Numbers: CAL02-001 : First Posted: October 22, 2015 Key Record Dates: Last Update Posted: January 27, 2020 Last Verified: January 2020

Clinicaltrials.gov   DA: 18 PA: 21 MOZ Rank: 42

Investing In Biomedical Discoveries

  • INVESTING IN BIOMEDICAL DISCOVERIES
  • LASCCO SA is a biomedical-technology development private company based at the Biopole of Lausanne, Switzerland
  • The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the

New.lascco.com   DA: 14 PA: 14 MOZ Rank: 32

Eagle To Licence Combioxin’s Antitoxin Agent For Pneumonia

  • Eagle Pharmaceuticals has signed a global licensing agreement with Switzerland-based clinical-stage biotechnology company Combioxin to gain the commercial rights to a new antitoxin agent, CAL02, to treat severe pneumonia
  • Designed to be an add-on treatment to antibiotics, CAL02 can potentially neutralise virulence effectors.

Healthcareradius.in   DA: 23 PA: 50 MOZ Rank: 78

Combioxin Enters Worldwide License Agreement With Eagle

  • Combioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals, Inc
  • (Nasdaq: EGRX), a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of …

Vischer.com   DA: 15 PA: 50 MOZ Rank: 71

Medical Breakthrough Reported In The Lancet ID

  • About Combioxin: Combioxin SA is a Swiss-based clinical-stage biotechnology company founded in 2015
  • The company is committed to the development of disruptive treatments for severe infections

Biospace.com   DA: 16 PA: 50 MOZ Rank: 73

Eagle Pharmaceuticals Announces Worldwide Licensing

  • WOODCLIFF LAKE, N.J., August 25, 2021--Eagle Pharmaceuticals, Inc
  • (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has entered into a worldwide licensing agreement with Combioxin SA ("Combioxin"), a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase …

Ca.movies.yahoo.com   DA: 19 PA: 50 MOZ Rank: 77

Combioxin SA – Swiss Biotech

Combioxin aims at becoming a market leader in non-traditional therapies for severe and resistant infections.

Swissbiotech.org   DA: 20 PA: 31 MOZ Rank: 60

Eagle Pharmaceuticals Announces Worldwide Licensing

  • Combioxin SA is a Swiss-based clinical-stage biotechnology company founded in 2015
  • The company is committed to the development of disruptive treatments for severe infections

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 80

CAL02 Liposomes And Other Antitoxins: A New Generation Of

  • Address correspondence to: Samareh Azeredo da Silveira, PhD, Combioxin SA, 8 rue de la Rôtisserie, Geneva 1204, Switzerland
  • E-mail: [email protected]
  • CAL02 Liposomes and Other Antitoxins: A New Generation of Anti-Infectives

Journals.lww.com   DA: 16 PA: 50 MOZ Rank: 77

CAL02, A Novel Antitoxin Liposomal Agent, In

  • P-FL reports personal fees from Combioxin, the funder of the trial, outside the submitted work
  • P-FD and TD's institutions received payments from Combioxin for the inclusion of patients in this trial
  • FL is a member of the board of directors of Combioxin, but has never received financial compensation from Combioxin for this position.

Thelancet.com   DA: 17 PA: 50 MOZ Rank: 79

Eagle Pharmaceuticals Announces Worldwide Licensing

  • WOODCLIFF LAKE, N.J., August 25, 2021--Eagle Pharmaceuticals, Inc
  • (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has entered into a worldwide licensing agreement with Combioxin

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 80

Combioxin Release: Data Monitoring Committee

10 October 2017 – Combioxin SA, a Swiss-based company specialising in the treatment of severe bacterial infections, announced today that an Independent Data Monitoring Committee has unanimously recommended continuation of the ongoing first-in-human trial in severely infected patients and High Dose continuation CAL02.

Biospace.com   DA: 16 PA: 50 MOZ Rank: 80

Eagle Pharmaceuticals Announces Worldwide Licensing

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia

Markets.ft.com   DA: 14 PA: 21 MOZ Rank: 50

500+ "Toni Perez" Profiles

  • View the profiles of professionals named "Toni Perez" on LinkedIn
  • There are 500+ professionals named "Toni Perez", who use LinkedIn to exchange information, ideas, and opportunities.

Linkedin.com   DA: 16 PA: 19 MOZ Rank: 51

Eagle To Licence Combioxin’s Antitoxin Agent For Pneumonia

  • CAL02 does not directly target the bacteria as against standard antibacterial drugs
  • Eagle Pharmaceuticals has signed a global licensing agreement with Switzerland-based clinical-stage biotechnology company Combioxin to gain the commercial rights to a new antitoxin agent, CAL02, to treat severe pneumonia.

Pharmaceutical-technology.com   DA: 33 PA: 40 MOZ Rank: 90

Development Of Non-Traditional Therapies For Bacterial

  • Registrants will receive email confirmation when they have been accepted
  • Persons without access to the Internet can call 301-796-1300 to register
  • Onsite registration on the day of the meeting

Fda.gov   DA: 11 PA: 50 MOZ Rank: 79

Eagle Pharmaceuticals Announces Worldwide Licensing

  • announced that it has entered into a worldwide licensing agreement with Combioxin SA (“Combioxin”), a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional …

Pharmajournalist.com   DA: 24 PA: 50 MOZ Rank: 93

600+ "Toni Pérez" Profiles LinkedIn

  • View the profiles of professionals named "Toni Pérez" on LinkedIn
  • There are 600+ professionals named "Toni Pérez", who use LinkedIn to exchange information, ideas, and opportunities.

Linkedin.com   DA: 16 PA: 25 MOZ Rank: 61

600+ "Toñi Perez" Profiles LinkedIn

  • View the profiles of professionals named "Toñi Perez" on LinkedIn
  • There are 600+ professionals named "Toñi Perez", who use LinkedIn to exchange information, ideas, and opportunities.

Linkedin.com   DA: 16 PA: 24 MOZ Rank: 61

Jobs With Combioxin SA

  • About Combioxin SA Combioxin SA is a clinical-stage company that develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains
  • The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves

Biospace.com   DA: 16 PA: 30 MOZ Rank: 68

«Work, Work, And Work Harder»

  • With the life-saving drug CAL02, Combioxin SA is revolutionizing the field of severe infections such as pneumonia
  • Managing Director Samareh Azeredo da Silveira Lajaunias explains how the spin-off successfully transforms the invention made at the Institute of Anatomy, University of Bern, to a market-ready pharmaceutical product.

Uniaktuell.unibe.ch   DA: 23 PA: 46 MOZ Rank: 92

Eagle Pharmaceuticals Announces Worldwide Licensing

  • Combioxin SA is a Swiss-based clinical-stage biotechnology company founded in 2015
  • The company is committed to the development of disruptive treatments for severe infections
  • Combioxin is a recipient of the Swiss FIT SEED program and is a spin-off of LASCCO SA, a company that propels academic discovery-stage inventions into life science ventures.

Stockhouse.com   DA: 14 PA: 50 MOZ Rank: 88

CAL02 Liposomes And Other Antitoxins: A New Generation Of

  • unacceptably high rates of treatment failure and mortality despite the best of care
  • This review presents the clinical stage broad-spectrum antitoxin agent CAL02, which is active against both gram-positive and gram-negative bacteria including ESKAPE pathogens
  • CAL02 neutralizes bacterial pore-forming toxins, enzymes, and toxin-effector virulent appendages that play a vital and upstream role in

Journals.lww.com   DA: 16 PA: 50 MOZ Rank: 91

Combioxin Escalates To High Dose In CAL02-001

Combioxin Escalates To High Dose In CAL02-001 Trial In Patients With Severe Pneumococcal Pneumonia Following IDMC's Positive Recommendation - read this article along with other careers information, tips and advice on BioSpace

Biospace.com   DA: 16 PA: 50 MOZ Rank: 92

Recently Analyzed

1: Rasmith.com 1 seconds ago

2: Gliderkit.com 3 seconds ago

3: Bjfwx.com 1 seconds ago

4: Pepsicobeveragefacts.com 1 seconds ago

5: Albendazoletablets.com 2 seconds ago

6: Tumvet.com 2 seconds ago

7: Brasilcard.net 1 seconds ago

8: Submittable.com 1 seconds ago

9: Jieyan-nosmoking.com 1 seconds ago

10: Parrellioptical.com 2 seconds ago

Tool Checker

Domain Expiry Date Updated

Expiry DateExpiry DateDomain ProviderHosting Provider
Parrellioptical.com9 years, 12 days leftNetwork Solutions, LLCLiquid Web, L.L.C
Jieyan-nosmoking.com 282 days leftKey-Systems GmbHLeaseweb USA, Inc.
Submittable.com1 year, 235 days leftGoDaddy.com, LLCGoogle LLC
Brasilcard.net6 years, 86 days lefteNom, LLCAmazon Technologies Inc.
Tumvet.com 108 days leftGoDaddy.com, LLCGoDaddy.com, LLC
Albendazoletablets.com 49 days leftHosting Concepts B.V. d/b/a OpenproviderCloudflare, Inc.
Pepsicobeveragefacts.com1 year, 129 days leftCSC Corporate Domains, Inc.Incapsula Inc
Bjfwx.com 197 days leftALIBABA.COM SINGAPORE E-COMMERCE PRIVATE LIMITEDPEG TECH INC
Gliderkit.com 139 days leftNetwork Solutions, LLCDosarrest Internet Security LTD
Rasmith.com 180 days leftGoDaddy.com, LLCGoogle LLC

<< See All >>

.COM - 10,595,200+   .ORG - 1,117,549+   .EDU - 123,500+   .NET - 792,945+   .GOV - 30,232+   .US - 84,439+   .CA - 122,904+   .DE - 220,061+   .UK - 272,390+   .IT - 108,882+   .AU - 152,812+   .CO - 51,739+   .BIZ - 59,081+   .IO - 32,494+   .NL - 99,647+   .SG - 19,713+   .INFO - 81,589+   .IE - 26,934+   .ME - 25,076+   .FR - 98,576+   .EU - 61,372+   .RU - 165,043+   .PH - 9,511+   .INT - 1,166+   .IN - 87,021+   .ES - 38,035+   .CZ - 71,869+   .VN - 48,920+   .TV - 14,250+   .SITE - 9,829+   .RO - 37,484+   .PL - 44,520+   .PK - 10,373+   .MOBI - 4,464+   .LK - 5,507+   .CN - 66,137+   .CH - 66,914+   .AT - 31,992+  

Email Address Search | IP Address Blacklist Check | Hosting Providers | Domain Providers | Website Error Checker

© 2018 Site-Stats.org. All rights reserved. Email: [email protected]